HeartFlow Logo
NOW FDA Cleared

Plaque Analysis

Enables risk assessment of
coronary artery disease

HeartFlow is the FIRST and ONLY company to non-invasively provide anatomy, physiology, and plaque information to help physicians confidently assess a patient's risk for coronary artery disease (CAD) and provide a personalized treatment plan.

Comprehensive

Plaque and FFRCT together offer a better understanding of patient risk.1

Accurate

Plaque assessment is highly correlated to IVUS for quantified plaque volumes for each vessel and lesion.2

Actionable

Specific plaque characteristics, such as low attenuation plaque, have proven to correlate with higher risk.3

Read the Press Release

HeartFlow’s NEW Plaque analysis provides data on the type of plaque present (Calcified, Non-calcified, Low-Attenuation)4 which can provide detailed information for physicians to understand patient risk, discuss heart health, and inform optimal medical treatment options.

Age and Sex-specific Nomographic CT Quantitative Plaque Data

Using a large international cohort, HeartFlow analyzed over 11,000 CCTAs to stratify total coronary atherosclerotic plaque volumes by age and sex.5 Physicians can utilize this data to help aid in optimizing patient management.



Quantitative Assessment of AI-based CCTA Plaque Volume

HeartFlow’s AI-based plaque from CCTA was shown to be as accurate compared to IVUS, the gold standard, showing a total plaque volume (TPV) correlation coefficient of 0.92 and a correlation coefficient of >0.90 to expert CT readers.2,4


Per Pullback
(n=50) 		Per Lesion
(n=83)
Total Plaque Volume0.850.92
Calcified Plaque Volume0.920.93
Non-calcified Plaque Volume0.830.89
Lumen Volume0.940.88
Vessel Volume0.910.93

Learn More About the HeartFlow Product Portfolio

FFRCT

Non-invasive cardiac test that provides personalized physiology information, delivering better per vessel diagnostic performance.3

More on FFRCT

RoadMap Analysis

The RoadMap analysis enables CT readers to identify stenoses in coronary arteries to support clinicians’ evaluation of CCTAs.

More on the RoadMap Analysis

REFERENCES

  1. Lee JM, Choi G, Koo BK, Hwang D, Park J, Zhang J, Kim KJ, Tong Y, Kim HJ, Grady L, Doh JH, Nam CW, Shin ES, Cho YS, Choi SY, Chun EJ, Choi JH, Nørgaard BL, Christiansen EH, Niemen K, Otake H, Penicka M, de Bruyne B, Kubo T, Akasaka T, Narula J, Douglas PS, Taylor CA, Kim HS. Identification of High-Risk Plaques Destined to Cause Acute Coronary Syndrome Using Coronary Computed Tomographic Angiography and Computational Fluid Dynamics. JACC Cardiovasc Imaging. 2019 Jun;12(6):1032-1043. doi: 10.1016/j.jcmg.2018.01.023. Epub 2018 Mar 14. Erratum in: JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 1):2288-2289. PMID: 29550316. EMERALD I.
  2. Multi-modality Imaging in Acute Myocardial Infarction(MIAMI), Robert Safian, MD, Beaumont Hospital, Royal Oaks, MI. Presented at SCCT July 2022.
  3. The SCOT-HEART Investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. Lancet 2015;385:2383-91.
  4. Data on File - HeartFlow. HeartFlow’s research on AI-based plaque from CCTA compared plaque volume within segments aligned to IVUS measurement locations.
  5. HeartFlow NOMOGRAM Data. Presented at SCCT July 2022.

173938284 v1